Patent ID: 8592589
Filing Date: 2013-11-26
Classification: A61K,A61P,C07D

Abstract:
1. A method for treating cancer in a mammal comprising (a) dissolving N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea solid crystalline form in a pharmaceutically acceptable solvent or mixture of solvents, wherein the crystalline form is characterized at least by a powder X-ray diffraction peak at any one or more of the following positions: 7.20, 8.37, 11.38, 16.75, 16.95, 19.60, 22.04, and 22.86° 2θ, ±0.2° 2θ; (b) administering the resulting solution in a therapeutically effective amount to subject having the disease; wherein the cancer is myelodysplastic syndrome, acute myeloid leukemia, colorectal cancer, non-small cell lung cancer, or ovarian cancer.